Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer

The Indiana University experience

M. Behnia, Richard Foster, Lawrence Einhorn, J. Donohue, C. R. Nichols

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Two cycles of bleomycin, etoposide, and cisplatin (BEP) were evaluated as adjuvant chemotherapy for patients with pathological stage II non- seminomatous germ cell tumours. Between 1985 and 1995, 86 patients with pathological stage II non-seminomatous testicular cancer were treated with two cycles of BEP. At retroperitoneal lymph node dissection (RPLND) 49 patients (57%) had pathological stage II(A) (microscopic nodal metastases) and 37 (43%) had stage II(B) (gross nodal metastases). After RPLND, the patients received bleomycin, 30 units weekly for 8 weeks, etoposide (100 mg/m2) and cisplatin (20 mg/m2) each for 5 days every 28 days for two cycles as adjuvant chemotherapy. 4 patients were lost to follow-up. 10 patients (12%) developed granulocytopenic fever during their chemotherapy. Of the 82 evaluable patients all remained with no evidence of disease except for a single patient with a cervical nodal relapse of teratoma. This was resected and he remains disease free. Median follow-up has been 85 months (range: 42- 173 months). In patients with fully resected stage II non-seminomatous germ cell tumour, two cycles of BEP were almost universally effective in preventing relapse. (C) 2000 Elsevier Science Ltd.

Original languageEnglish
Pages (from-to)472-475
Number of pages4
JournalEuropean Journal of Cancer
Volume36
Issue number4
DOIs
StatePublished - Mar 2000

Fingerprint

Bleomycin
Testicular Neoplasms
Etoposide
Cisplatin
Adjuvant Chemotherapy
Lymph Node Excision
Neoplasm Metastasis
Recurrence
Lost to Follow-Up
Teratoma
Fever
Drug Therapy

Keywords

  • Adjuvant
  • Bleomycin
  • Cisplatin
  • Etoposide
  • Testicular cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer : The Indiana University experience. / Behnia, M.; Foster, Richard; Einhorn, Lawrence; Donohue, J.; Nichols, C. R.

In: European Journal of Cancer, Vol. 36, No. 4, 03.2000, p. 472-475.

Research output: Contribution to journalArticle

@article{491a7a55ac5d4e08bad3a44c591702b0,
title = "Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer: The Indiana University experience",
abstract = "Two cycles of bleomycin, etoposide, and cisplatin (BEP) were evaluated as adjuvant chemotherapy for patients with pathological stage II non- seminomatous germ cell tumours. Between 1985 and 1995, 86 patients with pathological stage II non-seminomatous testicular cancer were treated with two cycles of BEP. At retroperitoneal lymph node dissection (RPLND) 49 patients (57{\%}) had pathological stage II(A) (microscopic nodal metastases) and 37 (43{\%}) had stage II(B) (gross nodal metastases). After RPLND, the patients received bleomycin, 30 units weekly for 8 weeks, etoposide (100 mg/m2) and cisplatin (20 mg/m2) each for 5 days every 28 days for two cycles as adjuvant chemotherapy. 4 patients were lost to follow-up. 10 patients (12{\%}) developed granulocytopenic fever during their chemotherapy. Of the 82 evaluable patients all remained with no evidence of disease except for a single patient with a cervical nodal relapse of teratoma. This was resected and he remains disease free. Median follow-up has been 85 months (range: 42- 173 months). In patients with fully resected stage II non-seminomatous germ cell tumour, two cycles of BEP were almost universally effective in preventing relapse. (C) 2000 Elsevier Science Ltd.",
keywords = "Adjuvant, Bleomycin, Cisplatin, Etoposide, Testicular cancer",
author = "M. Behnia and Richard Foster and Lawrence Einhorn and J. Donohue and Nichols, {C. R.}",
year = "2000",
month = "3",
doi = "10.1016/S0959-8049(99)00316-0",
language = "English",
volume = "36",
pages = "472--475",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer

T2 - The Indiana University experience

AU - Behnia, M.

AU - Foster, Richard

AU - Einhorn, Lawrence

AU - Donohue, J.

AU - Nichols, C. R.

PY - 2000/3

Y1 - 2000/3

N2 - Two cycles of bleomycin, etoposide, and cisplatin (BEP) were evaluated as adjuvant chemotherapy for patients with pathological stage II non- seminomatous germ cell tumours. Between 1985 and 1995, 86 patients with pathological stage II non-seminomatous testicular cancer were treated with two cycles of BEP. At retroperitoneal lymph node dissection (RPLND) 49 patients (57%) had pathological stage II(A) (microscopic nodal metastases) and 37 (43%) had stage II(B) (gross nodal metastases). After RPLND, the patients received bleomycin, 30 units weekly for 8 weeks, etoposide (100 mg/m2) and cisplatin (20 mg/m2) each for 5 days every 28 days for two cycles as adjuvant chemotherapy. 4 patients were lost to follow-up. 10 patients (12%) developed granulocytopenic fever during their chemotherapy. Of the 82 evaluable patients all remained with no evidence of disease except for a single patient with a cervical nodal relapse of teratoma. This was resected and he remains disease free. Median follow-up has been 85 months (range: 42- 173 months). In patients with fully resected stage II non-seminomatous germ cell tumour, two cycles of BEP were almost universally effective in preventing relapse. (C) 2000 Elsevier Science Ltd.

AB - Two cycles of bleomycin, etoposide, and cisplatin (BEP) were evaluated as adjuvant chemotherapy for patients with pathological stage II non- seminomatous germ cell tumours. Between 1985 and 1995, 86 patients with pathological stage II non-seminomatous testicular cancer were treated with two cycles of BEP. At retroperitoneal lymph node dissection (RPLND) 49 patients (57%) had pathological stage II(A) (microscopic nodal metastases) and 37 (43%) had stage II(B) (gross nodal metastases). After RPLND, the patients received bleomycin, 30 units weekly for 8 weeks, etoposide (100 mg/m2) and cisplatin (20 mg/m2) each for 5 days every 28 days for two cycles as adjuvant chemotherapy. 4 patients were lost to follow-up. 10 patients (12%) developed granulocytopenic fever during their chemotherapy. Of the 82 evaluable patients all remained with no evidence of disease except for a single patient with a cervical nodal relapse of teratoma. This was resected and he remains disease free. Median follow-up has been 85 months (range: 42- 173 months). In patients with fully resected stage II non-seminomatous germ cell tumour, two cycles of BEP were almost universally effective in preventing relapse. (C) 2000 Elsevier Science Ltd.

KW - Adjuvant

KW - Bleomycin

KW - Cisplatin

KW - Etoposide

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=0034012705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034012705&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(99)00316-0

DO - 10.1016/S0959-8049(99)00316-0

M3 - Article

VL - 36

SP - 472

EP - 475

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 4

ER -